INTRODUCTION: We report the impact of canakinumab, a fully human anti- @entity1356 monoclonal antibody, on @entity32 and health-related quality of life (HRQoL) in @entity1 with difficult-to-treat @entity3811 . METHODS: In this eight-week, single-blind, double-dummy, dose-ranging study, @entity1 with @entity3811 flares who were unresponsive or intolerant to--or had contraindications for--non-steroidal anti-inflammatory drugs and/or colchicine were randomized to receive a single subcutaneous dose of canakinumab (10, 25, 50, 90, or 150 mg) (N = 143) or an intramuscular dose of @entity2995 40 mg (N = 57). @entity1 assessed @entity158 using a Likert scale, physicians assessed clinical signs of @entity32 , and HRQoL was measured using the 36-item Short-Form Health Survey (SF-36) (acute version). RESULTS: At baseline, 98% of @entity1 were suffering from moderate-to-extreme @entity158 . The percentage of @entity1 with no or mild @entity158 was numerically greater in most canakinumab groups compared with @entity2995 from 24 to 72 hours post-dose; the difference was statistically significant for canakinumab 150 mg at these time points (P < 0.05). Treatment with canakinumab 150 mg was associated with statistically significant lower Likert scores for tenderness (odds ratio (OR), 3.2; 95% confidence interval (CI), 1.27 to 7.89; P = 0.014) and swelling (OR, 2.7; 95% CI, 1.09 to 6.50, P = 0.032) at 72 hours compared with @entity2995 . Median @entity1851 and serum amyloid A levels were normalized by seven days post-dose in most canakinumab groups, but remained elevated in the @entity2995 group. Improvements in physical health were observed at seven days post-dose in all treatment groups; increases in scores were highest for canakinumab 150 mg. In this group, the mean SF-36 physical component summary score increased by 12.0 points from baseline to 48.3 at seven days post-dose. SF-36 scores for physical functioning and bodily @entity158 for the canakinumab 150 mg group approached those for the US general population by seven days post-dose and reached norm values by eight weeks post-dose. CONCLUSIONS: Canakinumab 150 mg provided significantly greater and more rapid reduction in @entity158 and signs and symptoms of @entity32 compared with @entity2995 40 mg. Improvements in HRQoL were seen in both treatment groups with a faster onset with canakinumab 150 mg compared with @entity2995 40 mg. TRIAL REGISTRATION: clinicaltrials.gov: NCT00798369.

Canakinumab relieves symptoms of acute flares and improves health-related quality of life in @entity1 with difficult-to-treat @entity3811 by suppressing XXXX : results of a randomized, dose-ranging study.

@entity1 :: ('9606', 'Species') :: ['Patients', 'patients'] @entity32 :: ('MESH:D007249', 'Disease') :: ['inflammation', 'joint inflammation'] @entity2995 :: ('MESH:D014222', 'Chemical') :: ['triamcinolone acetonide'] @entity1356 :: ('3553', 'Gene') :: ['interleukin-1b'] @entity3811 :: ('MESH:D015210', 'Disease') :: ['Gouty Arthritis', 'acute Gouty Arthritis'] @entity158 :: ('MESH:D010146', 'Disease') :: ['pain'] @entity1851 :: ('1401', 'Gene') :: ['C-reactive protein']
@entity32 :: (MESH:D007249,Disease) :: ['inflammation']
